Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1997-02-12
2000-10-17
Clark, Deborah J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
4353201, A61K 4800, C12N 1563
Patent
active
061332445
ABSTRACT:
Nucleotide vector composition containing such vector and vaccine for immunization against hepatitis. Nucleotide vector comprising at least one gene or one complementary DNA coding for at least a portion of a virus, and a promoter providing for the expression of such gene in muscle cells. The gene may be the S gene of the hepatitis B virus. A nucleotide vector composition when administered to even chronic HBV carriers is capable of breaking T cell tolerance to the surface antigens of hepatitis B virus. A vaccine preparation containing said bare DNA is injected into the host previously treated with a substance capable of inducing a coagulating necrosis of the muscle fibers.
REFERENCES:
patent: 4769238 (1988-09-01), Rutter et al.
patent: 5256553 (1993-10-01), Overall et al.
patent: 5256767 (1993-10-01), Salk et al.
patent: 5310668 (1994-05-01), Ellis et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5639637 (1997-06-01), Thomas et al.
patent: 5643578 (1997-07-01), Robinson et al.
Mancini et al. DNA-mediated Immunization in a Transgenic Mouse Model of the Hepatitis B Surface Antigen Chronic Carrier State. PNAS, vol. 93, pp. 12496-12501, Oct. 1996.
Davis et al. DNA-based Immunization Induces Continuous Secretion of Hepatitis B Surface Antigen and High Levels of Circulating Antibody. Human Molecular Genetics, vol. 2, No. 11, pp. 1847-1851, 1993.
Babinet et al. Specific Expression of Hepatitis B Surface Antigen (HBsAg) in Transgenic Mice. Science, vol. 20, pp. 1160-1163, Dec. 6, 1985.
Mancini et al. Induction of Anti-Hepatitis B Surface Antigen (HBsAg) Antibodies in HBsAg Producing Transgenic Mice: A Possible Way of Circumventing "Nonresponse" to HBsAg. Journal of Medical Virology, vol. 39, pp. 67-74, 1993.
Davis, Heather L. DNA Vaccines for Prophylactic or Therapeutic Immunization Against Hepatitis B Virus. The Mount Sinai Journal of Medicine, vol. 66, pp. 84-90. Mar. 1999.
Chisari et al. A Transgenic Mouse Model of the Chronic Hepatitis B Surface Antigen Carrier State. Science, vol. 230, pp. 1157-1160. Dec. 6, 1985.
Akbar et al. Placebo-controlled Trial of Vaccination with Hepatitis B Virus Surface Antigen in Hepatitis B Virus Transgenic Mice. Journal of Hepatology, vol .26, pp. 131-137, 1997.
Araki et al. Expression and Replication of Hepatitis B Virus Genome in Transgenic Mice. PNAS, vol. 86, pp. 207-211, Jan. 1989.
Akbar et al. Hepatitis B Virus (HBV)-Transgenic Mice as an Investigative Tool to Study Immunopathology During HBV Infection. Int. J. Exp. Path., vol. 79, pp. 279-291, 1998.
Zinkernagel, R. M. Fundamental Immunology, 3rd edition. Raven Press, Paul, W.-editor. Chapter 34, pp. 1211-1250, 1993.
Ledley, F. Clinical Considerations in the Design of Protocols for Somatic Gene Therapy. Human Gene Therapy, vol. 2, pp. 77-83, 1991.
Okin et al. Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Distributed by the National Institutes of Health, Bethesda, MD, or www.nih.gov. Dec. 7, 1995.
Chattergoon et al. Genetic Immunization: A New Era in Vaccines and Immune Therapeutics. FASEB, vol. 11, pp. 753-763. Aug. 1997.
McDonnell et al. Molecular Medicine DNA Vaccines. The New England Journal of Medicine, vol. 334, pp. 42-45. Jan. 4, 1996.
B. Wang et al., PNAS, 90:4156-60 ('93).
Z. Li et al., Devel., 117:947-59 ('93).
M. Lubeck et al., PNAS, 86:6763-7 ('89).
P. Valenzuela et al., Nature, 298:347-350 ('82).
J. Ulmer et al., Science 251:1745-9 ('93).
C. Shihet et al., J. Virol. 67(10) 5823-32 ('93).
R. Cattaneo et al., Nature, 305:336-8 ('83).
D. Milich et al., J. Immunol. 137(1) 315-22 ('86).
D. Thomson et al., PNAS, 81:659-63 ('84).
B. Haynes et al., Science, 260:1279-86 ('93).
W. Szmuness et al., N. Engl. J. Med., 307(24) 1481-6 ('82).
W. Bohmet et al., J. Immunol. Med. 193:29-40 ('96).
Mancini Maryline
Michel Marie-Louise
Clark Deborah J.
Institut Pasteur
Institute National de la Sante et la Recherche Medicale
LandOfFree
Method for immunization against hepatitis B does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for immunization against hepatitis B, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for immunization against hepatitis B will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-468973